FDA July 2026 PCAC Meeting: What It Means for BPC-157, TB-500, and Peptide Access

The FDA's Pharmacy Compounding Advisory Committee will meet July 23-24, 2026 to review seven peptides for potential addition to the 503A Bulk Drug Substances List. BPC-157, TB-500, MOTS-c, and KPV are on the Day 1 agenda. Semax, Epitalon, and DSIP (Emideltide) will be reviewed on Day 2. A positive recommendation could establish a clear legal pathway for compounding pharmacies to prepare these peptides with prescriptions. A negative outcome could restrict access further. The public comment docket (FDA-2025-N-6895) closes July 22, 2026, but comments submitted by July 9 will be presented directly to the committee.

This is the most consequential regulatory event for peptide access in years. Here's what you need to know.

What Is the PCAC and Why Does This Meeting Matter?

The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which bulk drug substances should be allowed for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. When a substance appears on the 503A Bulk Drug Substances List, licensed compounding pharmacies can legally prepare patient-specific formulations with a valid prescription.

The July 2026 meeting follows a turbulent few years for peptide regulation. In late 2023, the FDA placed 19 peptides in Category 2, a designation indicating "significant safety risks" that effectively blocked compounding. On April 15, 2026, HHS announced that 12 peptides would be removed from Category 2 after their nominations were withdrawn. This removal became effective April 22, 2026.

However, removal from Category 2 does not automatically authorize compounding. These peptides now exist in a regulatory gray zone. The PCAC meeting will determine whether they move to Category 1 (approved for compounding) or potentially back to restricted status.

Which Peptides Are Being Reviewed?

The two-day meeting covers seven peptides across two sessions.

Day 1: July 23, 2026 (8:00 AM - 4:30 PM ET)

BPC-157 (Body Protection Compound-157)

• Forms under review: BPC-157 free base, BPC-157 acetate
• Proposed indication: Ulcerative colitis
• Background: BPC-157 is a 15-amino acid synthetic peptide derived from a protein found in human gastric juice. Preclinical research has examined its effects on wound healing, tendon repair, and gastrointestinal protection. It has been one of the most widely used peptides in longevity and sports medicine clinics.

TB-500 (Thymosin Beta-4 Fragment)

• Forms under review: TB-500 free base, TB-500 acetate
• Proposed indication: Wound healing
• Background: TB-500 is a synthetic 7-amino acid fragment corresponding to amino acids 17-23 of Thymosin Beta-4, the central actin-binding domain associated with cell migration and tissue repair. Research has focused on cardiac repair, neurological applications, and musculoskeletal recovery.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c)

• Forms under review: MOTS-c free base, MOTS-c acetate
• Proposed indications: Obesity, osteoporosis
• Background: MOTS-c is a 16-amino acid peptide encoded by mitochondrial DNA, discovered in 2015 by researchers at USC. It activates AMPK pathways and has been studied as an exercise mimetic that may improve glucose metabolism and insulin sensitivity.

KPV (Lysine-Proline-Valine)

• Forms under review: KPV free base, KPV acetate
• Proposed indications: Wound healing, inflammatory conditions
• Background: KPV is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone. At just three amino acids, it's one of the shortest therapeutic peptides under study. Research has focused on its ability to inhibit NF-kB activation and reduce inflammation in conditions like inflammatory bowel disease.

Day 2: July 24, 2026 (8:00 AM - 3:50 PM ET)

Emideltide (Delta Sleep-Inducing Peptide / DSIP)

• Forms under review: Emideltide free base, Emideltide acetate
• Proposed indications: Insomnia, opioid withdrawal
• Background: DSIP is a nine-amino acid neuropeptide originally isolated from rabbit brain tissue in 1974. It has been studied for sleep disorders and substance withdrawal, primarily in European research settings.

Semax

• Forms under review: Semax free base, Semax acetate
• Proposed indications: Cerebral ischemia, migraine, trigeminal neuralgia
• Background: Semax is a synthetic heptapeptide derived from ACTH, developed by Russian researchers in the 1980s. It has been used in Russian hospitals for stroke recovery and cognitive disorders. Research has examined neuroprotective and nootropic effects.

Epitalon (Epithalamin)

• Forms under review: Epitalon free base, Epitalon acetate
• Proposed indications: Sleep and aging-related outcomes
• Background: Epitalon is a synthetic tetrapeptide studied by Russian gerontologist Vladimir Khavinson. Research has focused on telomerase activation, melatonin regulation, and circadian rhythm. Human data remains limited.

What Outcomes Are Possible?

The PCAC provides recommendations to the FDA, not binding decisions. The committee will vote on whether each peptide should be added to the 503A Bulk Drug Substances List. Several outcomes are possible:

Positive Recommendation If the PCAC votes in favor and the FDA accepts the recommendation, the agency will initiate a formal rulemaking process to add the peptide to the 503A list. This process involves additional public comment periods and typically takes 12-18 months. Once complete, licensed 503A compounding pharmacies could legally prepare patient-specific formulations with valid prescriptions.

Negative Recommendation If the PCAC votes against inclusion, finding unacceptable safety risks, the FDA could place the peptide in the "Other Bulk Drug Substances That May Present Significant Safety Risks" category. This would effectively prohibit compounding under 503A.

Split or Conditional Recommendations The committee could recommend approval for some peptides while rejecting others. It could also recommend approval with specific conditions, such as requiring particular testing protocols or limiting approved indications.

FDA Discretion Regardless of the PCAC vote, the FDA retains authority to accept, modify, or reject recommendations. The agency could also announce enforcement discretion policies that allow compounding to continue while rulemaking proceeds.

Historical Context

In 2024, the PCAC voted against inclusion of peptides that came before it under the previous administration, finding they posed unacceptable safety risks. Whether the current political and regulatory environment produces different results remains uncertain.

How to Submit Public Comments

The FDA has established docket FDA-2025-N-6895 to collect public input on the seven peptides under review.

Key Deadlines

• July 9, 2026: Comments received by this date will be compiled and presented to the committee members before the meeting
• July 22, 2026: Final deadline for comments (11:59 PM ET). Comments received after July 9 but before this deadline will still be considered by the FDA

How to Submit

Electronic Submission (Recommended)

1. Visit regulations.gov
2. Search for docket FDA-2025-N-6895
3. Click "Submit a Formal Comment"
4. Follow the prompts to complete your submission

Written Submission Mail two copies to: Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852

For confidential submissions, include one copy marked "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION" and one redacted copy.

What to Include in Your Comment

The FDA evaluates comments based on law and science. Effective comments should:

• Clearly state your position on the specific peptide(s)
• Provide reasoning supported by evidence
• Reference the docket number (FDA-2025-N-6895)
• Include citations for any scientific claims
• Describe relevant personal or clinical experience
• Address safety considerations honestly

Comments from patients describing their experiences, practitioners presenting clinical observations, and researchers providing scientific analysis all carry weight. Generic form letters are less impactful than substantive, specific input.

Contact Information

Questions about the comment process: FDA Dockets Management: (240) 402-7500 Hours: 9 AM - 4 PM ET, Monday through Friday

What Does This Mean for Patients?

For patients currently using these peptides or considering them, the PCAC meeting creates both uncertainty and opportunity.

Current Access With the peptides removed from Category 2 as of April 22, 2026, some compounding pharmacies may continue filling prescriptions. However, this exists in a regulatory gray area. Pharmacies are making individual decisions about risk tolerance. Some have continued compounding while others have paused until the PCAC provides clarity.

If Approved A positive outcome would provide legal certainty. Patients with valid prescriptions could access compounded peptides from licensed pharmacies without ambiguity about regulatory status. Insurance coverage would remain unlikely, as these are not FDA-approved drugs.

If Rejected A negative outcome would likely end legal compounding under 503A. Patients would lose access to pharmacy-compounded formulations. Research chemical suppliers would remain, but those products are sold "for research purposes only" and carry quality and legal concerns.

Timeline Expectations Even with a positive PCAC vote, the formal rulemaking process takes 12-18 months. Patients should not expect immediate changes regardless of the meeting outcome. The FDA may announce interim enforcement discretion policies, but this is not guaranteed.

What Does This Mean for Practitioners?

Clinicians prescribing peptide therapies face regulatory uncertainty that the PCAC meeting could partially resolve.

Prescribing Considerations Until the FDA takes final action, prescribers must evaluate their own risk tolerance. The peptides are not FDA-approved for any indication. Removal from Category 2 does not constitute approval. Practitioners should:

• Document clinical rationale thoroughly
• Ensure informed consent addresses regulatory status
• Work with reputable compounding pharmacies
• Monitor state medical board guidance
• Stay informed on FDA announcements

Compounding Pharmacy Relationships Some 503A pharmacies have continued preparing peptides, while others have suspended operations pending regulatory clarity. Practitioners should confirm their pharmacy's policies and verify quality testing protocols.

State Variations State pharmacy boards and medical boards may have their own positions on peptide compounding. What the FDA permits, a state may still restrict. Practitioners should verify requirements in their jurisdiction.

Meeting Logistics

Dates: July 23-24, 2026

Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center (The Great Room), Silver Spring, Maryland

Virtual Option: The meeting will be accessible virtually. Registration details will be posted on the FDA advisory committee calendar page.

Schedule:

• Day 1: July 23, 8:00 AM - 4:30 PM ET
• Day 2: July 24, 8:00 AM - 3:50 PM ET

Public Attendance Both in-person and virtual attendance options are available. Space may be limited for in-person attendance. Check the FDA website for registration requirements.

The Bigger Picture

This meeting represents one step in an ongoing regulatory process. Even the best possible outcome does not mean these peptides become FDA-approved drugs. Compounding is a distinct regulatory pathway from drug approval.

What Approval Would Mean Addition to the 503A list would authorize licensed compounding pharmacies to prepare patient-specific formulations. This provides a legal pathway for clinical use with prescriptions. It does not:

• Constitute FDA approval for safety or efficacy
• Guarantee insurance coverage
• Remove WADA prohibitions for athletes
• Authorize over-the-counter sales
• Permit marketing claims about treating diseases

What Approval Would Not Change Athletes subject to WADA testing remain prohibited from using BPC-157, TB-500, MOTS-c, and other peptides on the banned list. Positive tests carry sanctions regardless of whether the peptide was legally prescribed by a physician.

Research chemical suppliers selling peptides "for research purposes only" operate in a separate regulatory space. The 503A compounding pathway affects pharmacies, not direct-to-consumer research chemical sales.

Frequently Asked Questions

When will we know the results of the PCAC meeting?

The committee votes during the meeting itself on July 23-24, 2026. Results will be public immediately. However, the FDA must then decide whether to accept recommendations and initiate rulemaking, which takes additional time.

Can I still get BPC-157 or TB-500 now?

Availability depends on your compounding pharmacy's policies. Some have continued operations, others have paused. Contact your pharmacy directly. Research chemical suppliers continue to sell these peptides, but those products are not intended for human use.

What if the PCAC votes against these peptides?

A negative vote would likely result in the peptides being categorized as posing significant safety risks, effectively prohibiting 503A compounding. The FDA could still exercise enforcement discretion, but this is uncertain.

Do I need to submit a comment for my voice to matter?

Comments that reach the FDA by July 9, 2026 will be directly presented to committee members. Your input genuinely influences the discussion, particularly if you provide specific clinical or personal experiences rather than generic statements.

Will insurance cover these peptides if approved for compounding?

Unlikely. Addition to the 503A list authorizes compounding, not FDA drug approval. Insurance coverage requires approved drugs with established coverage policies.

How is this different from the GLP-1 compounding situation?

GLP-1 agonists like semaglutide are FDA-approved drugs currently in shortage, which creates a separate compounding pathway under shortage provisions. The peptides under PCAC review have never been FDA-approved and are being evaluated under standard 503A criteria.

Key Takeaways

• The FDA PCAC meets July 23-24, 2026 to review seven peptides: BPC-157, TB-500, MOTS-c, KPV, Emideltide (DSIP), Semax, and Epitalon
• A positive recommendation could establish legal compounding pathways, though formal rulemaking takes 12-18 months
• Public comments are due by July 9, 2026 to be presented to the committee, with the docket open until July 22
• Even with approval, these peptides would not become FDA-approved drugs, and WADA prohibitions remain for athletes
• Patients and practitioners face continued uncertainty until the FDA takes final action following the meeting

Conclusion

The July 2026 PCAC meeting represents the most significant regulatory moment for therapeutic peptides in recent memory. After years of uncertainty following the Category 2 designations in 2023, and the subsequent removal in April 2026, this meeting could establish a clear legal framework for peptide compounding.

The outcome is not predetermined. The 2024 PCAC meetings resulted in negative recommendations for the peptides then under review. Whether the current environment produces different results depends on the evidence presented, the committee's assessment, and the FDA's subsequent decisions.

For those invested in peptide access, the path forward involves submitting substantive public comments by July 9, following the meeting proceedings, and preparing for multiple possible outcomes. Regulatory clarity, whatever form it takes, will benefit patients and practitioners who currently navigate an ambiguous landscape.

This content is for informational purposes only and does not constitute medical or legal advice. Peptides discussed in this article are not FDA-approved for human use. Consult a qualified healthcare provider before considering any peptide therapy.

Sources

• FDA Advisory Committee Calendar: July 23-24, 2026 PCAC Meeting
• Federal Register: PCAC Notice of Meeting (April 16, 2026)
• FDA Bulk Drug Substances Nominated for Use in Compounding (Updated April 22, 2026)
• Orrick: FDA Announces Removal of 12 Peptides from Category 2
• Frier Levitt: FDA Peptide Update 2026
• National Law Review: FDA to Consider Lifting Restrictions on Numerous Compounded Peptides
• RAPS: FDA Considers Adding Peptides to Bulk Drug Compounding List
• PMC: MOTS-c as a Mitochondrial-Derived Peptide
• Cell Metabolism: MOTS-c Promotes Metabolic Homeostasis
• PMC: Orally Targeted Delivery of KPV for Ulcerative Colitis